Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entrectinib vs Crizotinib in ROS1-positive NSCLC
NCT04603807Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Sep 2021
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of entrectinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival in participants with central nervous system metastases at baseline up to 7 years. Started Sep 2021; status: active, not recruiting.
02
Drugs
entrectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04603807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603807.